The statements made in this presentation may include forward-looking statements regarding the treatment of orthopoxvirus infections, the development and attributes of SIGA Technologies, Inc. ("SIGA") products, and the future operations, opportunities or financial performance of SIGA. Although we believe that the expectations contained in this presentation are reasonable, these forward-looking statements are only estimations based upon the information available to SIGA as of the date of this presentation. Except as required by law, we expressly disclaim any responsibility to publicly update or revise our forward-looking statements, whether as a result of new information, future events or otherwise. Thus, the forward-looking statements herein involve known and unknown risks and uncertainties and other important factors such that actual future operations, opportunities or financial performance may differ materially from these forward-looking statements.

Undue reliance should not be placed on forward looking statements, which speak only as of the date hereof. All forward-looking statements contained herein are qualified in their entirety by the foregoing cautionary statements.

For a more detailed discussion of our risks, see the Risk Factors section in SIGA’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed with the SEC and our other filings with the SEC, including our most recent Quarterly Report, all of which are available on our website, www.siga.com.
## SIGA Value Proposition

| Growing Public-Private Markets | • Biodefense is a $9.5B global market with an 8.3% CAGR\(^1\)  
<table>
<thead>
<tr>
<th></th>
<th>• Attractive market expansion opportunities</th>
</tr>
</thead>
</table>
| Critical Need                | • Bioterrorism is a recognized, urgent threat that could kill millions in a single outbreak  
|                              | • Smallpox is one of the deadliest threats with a historical 30% fatality rate  
|                              | • Vaccines alone cannot address a smallpox outbreak |
| Favorable Policy and Regulatory Environment | • Unique market dynamics, regulations and policies support multiple potential revenue streams for the TPOXX product line |
| Proven Track Record           | • Experienced management and strategic collaborations enhance prospects for success  
|                              | • Over $500 million in contract awards from the U.S. Government  
|                              | • Highly externalized cost structure minimizes fixed costs and provides scalability |
| Multiple Catalysts for Growth | • Significant opportunities for value creation around SIGA’s antiviral therapy for smallpox |

\(^1\) Grand View Research, Published October 2016.
## Lead Program TPOXX Current and Potential Revenue

<table>
<thead>
<tr>
<th>Revenue Streams</th>
<th>Description / Status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral Drug (U.S. Gov)</strong></td>
<td>• Procurement and Development Contract of $472 million for 2 million courses of drug for 18-64 yr. olds; potential expansion for coverage of all ages</td>
</tr>
<tr>
<td></td>
<td>• Replenishment of product deliveries that started in 2013</td>
</tr>
<tr>
<td></td>
<td>• Potential future expanded indication for post-exposure prophylaxis based on additional studies</td>
</tr>
<tr>
<td><strong>IV drug (U.S. Gov)</strong></td>
<td>• Currently in Phase 1 development; granted fast track status</td>
</tr>
<tr>
<td></td>
<td>• Enrollment in Phase 1a study completed</td>
</tr>
<tr>
<td></td>
<td>• Development contract from U.S. Government</td>
</tr>
<tr>
<td><strong>Priority Review Voucher (PRV)</strong></td>
<td>• 21st Century Cures Act established PRV program for Medical Countermeasures</td>
</tr>
<tr>
<td></td>
<td>• Potential eligibility for PRV upon NDA approval for TPOXX (anticipated in 2018)</td>
</tr>
<tr>
<td><strong>International</strong></td>
<td>• Focused business development program in numerous countries</td>
</tr>
<tr>
<td></td>
<td>• FDA approval of TPOXX is a key milestone to support procurement planning</td>
</tr>
<tr>
<td><strong>Private Sector</strong></td>
<td>• Hospitals, large corporations, and specialty retail stockpiles for emergency use</td>
</tr>
</tbody>
</table>

Substantial NOLs providing tax benefits for current BARDA contract and future contracts
Smallpox: A Deadly Killer

- Smallpox has a **potential 30% fatality rate** and was responsible for approximately **300 million deaths** worldwide in the 20th century.

- Smallpox is a **highly contagious** virus
  - Spreads person to person
  - Can be transmitted through speaking, breathing, or touching
  - Can be transmitted by direct contact with infected fluids and contaminated objects
  - It is estimated that each person infected with smallpox would infect 5-7 other people if not vaccinated/treated.

- Successful eradication resulted from coordinated global vaccination campaigns.

- Current smallpox vaccine and other vaccinia-based vaccines may cause serious adverse reactions, especially in individuals who are very young or very old, or immunocompromised (e.g., those with eczema or atopic dermatitis).
Compassionate Use in Treatment of Vaccine Complications

2007
- **28-month old child**\(^1\)\(^-\)\(^3\)
  Diagnosed with eczema vaccinatum after contact with his father, an active U.S. military service member who had recently received smallpox vaccination

2009
- **20-year old active U.S. military service member**\(^4\)\(^,\)\(^5\)
  Presented with progressive vaccinia after receiving smallpox vaccination
- **35-year old female**\(^6\)
  Developed a vaccinia infection after exposure to a recombinant vaccinia-based rabies vaccine

2011
- **25-year old female**
  Developed a vaccinia infection after changing a bandage covering a smallpox vaccination site for her boyfriend, a U.S. military contractor

2015
- **Active U.S. military male service member**
  Developed vaccine complications due to a concomitant undiagnosed cancer

The Challenges of Smallpox Today

- **Today’s population is not immune from smallpox**: 1
- **Smallpox vaccine cannot treat all individuals**: 2
- **Treatment with vaccine must be immediate**: 3
- **Immediate treatment nearly impossible**: 1

<table>
<thead>
<tr>
<th>Year</th>
<th>Percentage</th>
<th>Days</th>
<th>Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>1980</td>
<td>20%</td>
<td>4</td>
<td>14</td>
</tr>
</tbody>
</table>

- Smallpox eradicated; routine vaccinations and boosters ceased
- Percent of the population contraindicated for vaccination
- Treatment window when patients receiving vaccine benefit after infection
- Period when infected individuals typically do not show symptoms

“Somebody would reconstruct, say, a smallpox virus and have that spread, and that would not only kill millions, it could potentially kill billions.”
*Bill Gates on bioterrorism, Jan 28, 2017, PBS*

“...the next epidemic could originate on the computer screen of a terrorist intent on using genetic engineering to create a synthetic version of the smallpox virus ...”
*Bill Gates, Feb 18, 2017, Business Insider Op-Ed*
Significant Government Investment in Preparedness

- U.S. government initiatives to support preparedness:
  - Project Bioshield (2004)
  - Formation of the Biomedical Advanced Research and Development Authority - BARDA (2006)
    - Supports development and procurement of countermeasures for bioterrorism attacks, including drugs considered priorities for national health security
    - Smallpox identified as a major threat
  - Pandemic and All-Hazards Preparedness Act Reauthorization (2014)

- Between 2001 and 2014, the U.S. government spent nearly $79 BILLION on civil biodefense funding\(^1\)

\(^1\)Sell TK and Watson M. Biosec Bioterror. 2013;11:196-216. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778993/.
Attributes of an Ideal Smallpox Therapeutic

Easy to...

STORE
Small molecule with long shelf life

TRANSPORT
Stable without the need for refrigeration

ADMINISTER
Oral and IV formulations

TPOXX is one of the first new molecular entity drugs delivered to the Strategic National Stockpile under Project BioShield
The Impact of an Antiviral on a Smallpox Attack
Smallpox is Highly Contagious and Deadly

It is estimated that, in the absence of a vaccine or antiviral therapy, each person infected with smallpox will infect 5-7 other people, and that approximately 30% of infected individuals will die.

Even with vaccination, published models have shown the use of an antiviral drug during an outbreak could significantly reduce fatalities, confirming the importance of maintaining significant stockpiles.

Sources: Centers for Disease Control, World Health Organization, Center for Infectious Disease Research and Policy, National Center for Biotechnology Information, Journal of Biosecurity and Bioterrorism, and presented to HHS, CDC, BARDA, FBI, Homeland Security, DoD, the White House and overseas.
SIGA is Uniquely Positioned to Address the Threat of Smallpox
MISSION
A commercial-stage specialty pharma company focused on developing solutions to infectious disease and biothreats

VALUABLE THERAPEUTIC PORTFOLIO

*TPOXX® (tecovirimat)*
- Oral capsule smallpox antiviral
  - Targeting NDA filing in late 2017
  - >$500 million of contract awards from U.S. Government
- IV formulation smallpox antiviral
  - Enrollment in Phase 1a study completed
  - Development contract from U.S. Government

Dengue Virus Antiviral
- Preclinical: efficacy shown in animal models
TPOXX Mechanism of Action

- Smallpox spreads by developing a secondary envelope
- This allows the virus to leave the cell and enter the bloodstream
- TPOXX’s mechanism of action inhibits maturation, preventing release and spread of viral particles to other cells

Inhibits the viral envelope formation and spread of the virus

# Therapeutic Portfolio: R&D and Sales

## R&D Status

<table>
<thead>
<tr>
<th>Program</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>NDA Approval</th>
<th>Status</th>
<th>Next Steps</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPOXX - Oral</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Completed</td>
<td>Enrollment of all Trials</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NDA submission – Q4 2017</td>
<td></td>
</tr>
<tr>
<td>TPOXX – IV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Completed Phase I a</td>
<td>Phase 1 b Initiation</td>
</tr>
</tbody>
</table>

## Procurement Status

<table>
<thead>
<tr>
<th>Program</th>
<th>Procurement Eligible</th>
<th>Stockpile maintenance</th>
<th>Status</th>
<th>Next Steps</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPOXX - Oral</td>
<td>$472 M&lt;sup&gt;1&lt;/sup&gt;</td>
<td></td>
<td>Delivering on Initial procurement</td>
<td>Stockpile maintenance and potential expansion</td>
</tr>
<tr>
<td>TPOXX – IV</td>
<td></td>
<td></td>
<td>R&amp;D funded</td>
<td>Establish procurement contract</td>
</tr>
</tbody>
</table>

<sup>1</sup> Procurement and Development Contract
Favorable Policy and Regulatory Environment Support Development and Future Demand for TPOXX
### Novel Development Path for TPOXX

#### Development Path
- With smallpox declared eradicated in 1980, it is unethical to conduct efficacy testing in humans
- FDA ‘animal rule’ established to conduct efficacy studies in animals and safety studies in humans
- Required GLP efficacy studies completed in animals along with animal toxicology
- Sale of product for stockpiling prior to NDA approval

#### TPOXX Status
- All Phase 3 clinical studies complete with no drug-related SAEs
- Dose concurrence agreement with FDA
- In vivo toxicology data and CMC data complete and being prepared for submission
- SIGA preparing NDA, with submission targeted for 4Q 2017
- Fast Track Designation and Orphan Drug Designation received, with anticipated NDA priority review

---

Anticipated to be first novel small-molecule drug to be approved for biodefense
Clinical Summary

Summary of Subjects Treated

<table>
<thead>
<tr>
<th>Number of Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Received at least one dose of TPOXX</td>
</tr>
<tr>
<td>Received at least 14 days of treatments</td>
</tr>
<tr>
<td>Drug-related Serious Adverse Events</td>
</tr>
</tbody>
</table>

Clinical Trial Summary

<table>
<thead>
<tr>
<th>Clinical Trial Summary</th>
<th>Phase 1 Trials (Completed)</th>
<th>Phase 2 Trials (Completed)</th>
<th>Pivotal Phase 3 Trial (Completed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Trials</td>
<td>11</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
</tbody>
</table>
Priority Review Voucher

- 21st Century Cures Act of 2016 created Priority Review Voucher (PRV) eligibility for Medical Countermeasures to material threats as determined by the U.S. Government

- Legislation provides the sponsor of a qualifying product with a PRV to receive priority review for a future drug of their choice, resulting in an accelerated review

- PRV may be sold commercially without restriction

- Smallpox is on the list of Material Threats, and TPOXX is a novel treatment for smallpox

- SIGA expects to apply for a PRV when the TPOXX NDA is filed; targeted for late 2017

- Upon NDA approval, FDA will determine eligibility and can award PRV. Targeted timing is 2H 2018

---

1U.S. House of Representatives Amendment to the Senate Amendment to H.R.34.Subtitle H – Medical Countermeasures Innovation. Available at:http://docs.house.gov/billsthisweek/20161128/CPRT-114-HPRT-RU00-SAHR34.pdf.
Elements in Place For Manufacturing and Commercial Success
U.S. Government Investment in Biodefense has Enabled SIGA to Build a Robust Capability for Drug Development and Commercialization

End-to-end network of proven partners established

- Over 20 partnered companies
- TPOXX developed from lead identification through commercial supply chain
- U.S. based supply chain for robust product supply to customers
- Experienced oversight of network by SIGA leadership
- Proven capabilities that can be scaled for future products

Network design minimizes fixed costs and provides ability to scale to product development and procurement demands.
Biodefense is an Attractive Specialty Market...

**MARKET INCENTIVES**

- **R&D**: Government provides majority of R&D funding
- **Limited Buyers with Pre-Defined Volume**: Procurement contracts typically awarded multiple years prior to anticipated NDA, providing early cash flow
- **Priority Review Voucher**: Potential eligibility upon NDA approval, lucrative secondary market
- **Technology / Capability Platform Building**: Opportunity to build technology and expertise in product fields
- **Capital Investment**: In specialized products, shared capital investments have been made to build infrastructure for supply chain and/or R&D
- **High Barriers to Entry**: Complex government contracting requirements and long procurement cycles

**...that strategically overlaps with broader infectious disease markets.**

Proven SIGA Leadership Team

Phillip Gomez, Ph.D., CEO
25+ years experience in Infectious Disease, Pharmaceuticals

Daniel Luckshire, EVP, CFO
20+ years experience in Specialty Business, Finance

Dennis Hruby, Ph.D., Chief Scientific Officer
25+ years experience in Microbiology, Pharmaceuticals

Robin Abrams, General Counsel and Chief Administrative Officer
25+ years experience in Law, Government, Pharmaceuticals

Tove Bolken, SVP, Operations
15+ years experience in Microbiology, Pharmaceuticals

Annie Frimm, VP, Regulatory, Clinical, & Quality
25+ years experience in Pharmaceuticals

Akhila Kosaraju, M.D., VP, Global Business Development
10+ years experience in Pharmaceuticals, Government

Eric Rose, M.D., Executive Chairman
25+ years experience in Healthcare
Corporate Focus: 2017-2018

- Obtain FDA Approval for TPOXX
- Expand Sales of TPOXX Product Line
- Optimize Value of PRV Opportunity
- Leverage Proven Networked Capabilities
- Maximize Shareholder Returns

1 Grand View Research, Published October 2016.